Tech Transfer eNews Blog
University-Industry Engagement Advisor

Stanford and Denovo Biopharma sign license agreement for heart disease treatment

By Jesse Schwartz
Published: June 6th, 2018

The Stanford University School of Medicine and Denovo Biopharma, a company that uses precision medicine to develop innovative therapies, have entered into an exclusive global license agreement to advance a treatment for pulmonary aerial hypertension (PAH) and emphysema.

The treatment, known as DB102 and originally developed as a cancer therapeutic, is based on the work of Stanford researcher Edda Spiekerkoetter and has been shown to prevent and reverse experimental hypertension progression in preclinical models.

PAH is a life-threatening disease that includes an increased pulmonary vascular resistance and an elevation of pulmonary pressure. The disease leads to right heart failure and, if not properly treated, death.

“We are now able to expand DB102 development beyond oncology and into PAH, which is a significant unmet medical need,” says Denovo CEO Wen Luo.

“This new development allows DB102 to expand into unexpected new indications through traditional drug repurposing efforts, which complements Denovo’s unique precision medicine approach of rescuing drugs through biomarker identification in their original indication,” Luo says. “We will evaluate DB102’s activity in patients with PAH in the near future.”

Source: PR Newswire

Easy eNPV is a new software tool that provides its users with unprecedented ability to efficiently and accurately forecast the financial performance of new drug candidates and produce valuations. CLICK HERE for details and an online demo

Posted under: Tech Transfer e-News

Twitter Facebook Linkedin Pinterest Email

No Comments so far ↓

There are no comments yet...Kick things off by filling out the form below.

Leave a Comment